During the past week, Regeneron Pharmaceuticals (NASDAQ: REGN) has experienced a number of challenges and opportunities. Starting with the negatives, REGN appeared amidst the
top 10 large cap losers last week according to a list. Also,
Leerink analysts downgraded the company to a 'Market Perform Hold' after a negative preliminary injunction ruling regarding Eylea's 2mg biosimilar. Conversely,
Regeneron also had significant victories, including
FDA approval for its drug developed in partnership with
Sanofi to treat COPD. Furthermore, the company's stock was recognized as a
long-term defensive investment. Despite legal setbacks leading to worst month in two years,
Regeneron plans to report Q3 2024 financial results and offer a webcast on October 31, 2024. Recently,
Granite FO LLC and Susquehanna Fundamental Investments LLC acquired new positions in Regeneron. Meanwhile,
SNY's Dupixent received CHMP recommendation for label expansion. Despite these developments, Regeneron's stock underperformed compared to competitors on several trading days throughout the week, and a lawsuit against directors is pending.
Regeneron Pharmaceuticals REGN News Analytics from Sat, 09 Mar 2024 08:00:00 GMT to Sun, 29 Sep 2024 17:25:13 GMT -
Rating -3
- Innovation 7
- Information 8
- Rumor -6
